Want to see GRCE full AI Analyst Report?
GRCE Stock Chart & Stats
$2.33
-$0.02(-0.85%)
At close: 4:00 PM EDT
$2.33
-$0.02(-0.85%)
Day’s Range― - ―
52-Week Range$1.79 - $5.18
Previous CloseN/A
Volume127.09K
Average Volume (3M)58.56K
Market Cap
$33.85M
Enterprise Value$15.68M
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding16,274,027
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.84K
Enterprise Value/Ebitda-1.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageEssentially no debt and roughly $64M of equity in 2026 materially reduce refinancing and interest risks. This financial flexibility supports remediation, regulatory activities, and technology transfer efforts without immediate dependence on dilutive financing, improving the company’s ability to execute near-term development milestones.
Pivotal Phase 3 Success And Orphan DesignationA positive pivotal trial and orphan designation create a durable commercial and regulatory advantage: stronger clinical credibility, potential expedited pathways, and pricing leverage in a rare severe indication. Layered IP and targeted strategy enhance long-term market exclusivity and commercial upside if approved.
Dual-source Manufacturing Strategy UnderwayAdvancing a second U.S.-based contract manufacturer and technology transfer reduces single-supplier concentration and addresses facility-level cGMP risk. Establishing multiple compliant supply routes increases resilience for approval, launch and scale, lowering structural manufacturing and regulatory execution risk over the medium term.
Bears Say
Pre-commercial: Zero RevenueThe company has recorded no commercial revenue for multiple years, meaning value realization depends entirely on successful NDA resubmission and eventual market launch. Absent commercialization, the firm lacks operating cash generation, making long-term scalability and profitability contingent on execution and approval outcomes.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows require ongoing external financing to fund operations, regulatory work and manufacturing transfers. While burn improved, continued negative cash generation constrains strategic flexibility, increases dilution risk and could limit the company’s ability to invest in commercialization readiness without new capital.
CMC/manufacturing Deficiencies Cited In FDA CRLThe CRL’s focus on facility-level cGMP issues and additional non-clinical CMC data creates structural approval and timing risk. Remediation, additional studies and potential FDA reinspection can be costly and time-consuming, potentially delaying resubmission, approval and eventual revenue realization even though no clinical deficiencies were cited.
Grace Therapeutics News
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.79 and its highest was $5.18 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $33.85M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Jun 18, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.17.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Overvalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 16,274,027 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 7.207%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.48%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
8.06%
Insiders
2.50% Mutual Funds
<0.01% Other Institutional Investors
86.75% Public Companies and
Individual Investors